These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 26185174)

  • 1. Concomitant systemic and central nervous system non-Hodgkin lymphoma: the role of consolidation in terms of high dose therapy and autologous stem cell transplantation. A 60-case retrospective study from LYSA and the LOC network.
    Damaj G; Ivanoff S; Coso D; Ysaebert L; Choquet S; Houillier C; Parcelier A; Abarah W; Marjanovic Z; Gressin R; Garidi R; Diouf M; Gac AC; Dupuis J; Troussard X; Morschhauseur F; Ghesquières H; Soussain C;
    Haematologica; 2015 Sep; 100(9):1199-206. PubMed ID: 26185174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiotepa, busulfan, and cyclophosphamide or busulfan, cyclophosphamide, and etoposide high-dose chemotherapy followed by autologous stem cell transplantation for consolidation of primary central nervous system lymphoma.
    Hyung J; Hong JY; Yoon DH; Kim S; Park JS; Park CS; Lee SW; Kim JH; Ryu JS; Huh J; Suh C
    Ann Hematol; 2019 Jul; 98(7):1657-1664. PubMed ID: 30989325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
    Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
    BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose Thiotepa, Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation as Upfront Consolidation for Systemic Non-Hodgkin Lymphoma With Synchronous Central Nervous System Involvement.
    Qualls D; Sullivan A; Li S; Brunner AM; Collier K; Hochberg E; Armand P; Batchelor TT; Chen YB; DeFilipp Z
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):884-888. PubMed ID: 28870642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial.
    Ferreri AJM; Cwynarski K; Pulczynski E; Fox CP; Schorb E; La Rosée P; Binder M; Fabbri A; Torri V; Minacapelli E; Falautano M; Ilariucci F; Ambrosetti A; Roth A; Hemmaway C; Johnson P; Linton KM; Pukrop T; Sønderskov Gørløv J; Balzarotti M; Hess G; Keller U; Stilgenbauer S; Panse J; Tucci A; Orsucci L; Pisani F; Levis A; Krause SW; Schmoll HJ; Hertenstein B; Rummel M; Smith J; Pfreundschuh M; Cabras G; Angrilli F; Ponzoni M; Deckert M; Politi LS; Finke J; Reni M; Cavalli F; Zucca E; Illerhaus G;
    Lancet Haematol; 2017 Nov; 4(11):e510-e523. PubMed ID: 29054815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation--an International Primary Central Nervous System Lymphoma Study Group project.
    Bromberg JE; Doorduijn JK; Illerhaus G; Jahnke K; Korfel A; Fischer L; Fritsch K; Kuittinen O; Issa S; van Montfort C; van den Bent MJ
    Haematologica; 2013 May; 98(5):808-13. PubMed ID: 23144196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.
    Omuro A; Correa DD; DeAngelis LM; Moskowitz CH; Matasar MJ; Kaley TJ; Gavrilovic IT; Nolan C; Pentsova E; Grommes CC; Panageas KS; Baser RE; Faivre G; Abrey LE; Sauter CS
    Blood; 2015 Feb; 125(9):1403-10. PubMed ID: 25568347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
    Abrey LE; Moskowitz CH; Mason WP; Crump M; Stewart D; Forsyth P; Paleologos N; Correa DD; Anderson ND; Caron D; Zelenetz A; Nimer SD; DeAngelis LM
    J Clin Oncol; 2003 Nov; 21(22):4151-6. PubMed ID: 14615443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma.
    Alvarnas JC; Negrin RS; Horning SJ; Hu WW; Long GD; Schriber JR; Stockerl-Goldstein K; Tierney K; Wong R; Blume KG; Chao NJ
    Biol Blood Marrow Transplant; 2000; 6(3A):352-8. PubMed ID: 10905773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation.
    Schorb E; Kasenda B; Atta J; Kaun S; Morgner A; Hess G; Elter T; von Bubnoff N; Dreyling M; Ringhoffer M; Krause SW; Derigs G; Klimm B; Niemann D; Fritsch K; Finke J; Illerhaus G
    Haematologica; 2013 May; 98(5):765-70. PubMed ID: 23300179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: A retrospective multicenter study.
    Perry C; Ben Barouch S; Goldschmidt N; Sarid N; Herishanu Y; Shvidel L; Bairey O; Lavi N; Horowitz N; Avigdor A; Lebel E; Sofer O; Ram R; Avivi I
    Am J Hematol; 2019 Sep; 94(9):992-1001. PubMed ID: 31211434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission.
    DeFilipp Z; Li S; El-Jawahri A; Armand P; Nayak L; Wang N; Batchelor TT; Chen YB
    Cancer; 2017 Aug; 123(16):3073-3079. PubMed ID: 28369839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance.
    Wight JC; Yue M; Keane C; Johnston A; Linton K; Chin C; Wai SH; Talaulikar D; Gasiorowski R; Cheah CY; Gregory GP; Dickinson M; Minson A; Coombes C; Ku M; Lam S; Hawkes EA
    Br J Haematol; 2019 Oct; 187(2):174-184. PubMed ID: 31236941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement.
    Kasamon YL; Jones RJ; Piantadosi S; Ambinder RF; Abrams RA; Borowitz MJ; Morrison C; Smith BD; Flinn IW
    Biol Blood Marrow Transplant; 2005 Feb; 11(2):93-100. PubMed ID: 15682069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved survival outcomes despite older age at diagnosis: an era-by-era analysis of patients with primary central nervous system lymphoma treated at a single referral centre in the United Kingdom.
    Kaji FA; Martinez-Calle N; Bishton MJ; Figueroa R; Adlington J; O'Donoghue M; Smith S; Byrne P; Paine S; Sovani V; Auer D; James E; Bessell EM; Grainge MJ; Fox CP
    Br J Haematol; 2021 Nov; 195(4):561-570. PubMed ID: 34368948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma.
    Chen YB; Batchelor T; Li S; Hochberg E; Brezina M; Jones S; Del Rio C; Curtis M; Ballen KK; Barnes J; Chi AS; Dietrich J; Driscoll J; Gertsner ER; Hochberg F; LaCasce AS; McAfee SL; Spitzer TR; Nayak L; Armand P
    Cancer; 2015 Jan; 121(2):226-33. PubMed ID: 25204639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line high-dose therapy and autologous blood stem cell transplantation in patients with primary central nervous system non-Hodgkin lymphomas-a single-centre experience in 61 patients.
    Brezina T; von Dewitz H; Schroeder T; Ullrich S; Nachtkamp K; Reifenberger G; Malzkorn B; Sabel M; Haas R; Kobbe G
    Ann Hematol; 2022 Mar; 101(3):607-616. PubMed ID: 34982196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upfront consolidation combining yttrium-90 ibritumomab tiuxetan and high-dose therapy with stem cell transplantation in poor-risk patients with diffuse large B cell lymphoma.
    Fruchart C; Tilly H; Morschhauser F; Ghesquières H; Bouteloup M; Fermé C; Van Den Neste E; Bordessoule D; Bouabdallah R; Delmer A; Casasnovas RO; Ysebaert L; Ciappuccini R; Briere J; Gisselbrecht C
    Biol Blood Marrow Transplant; 2014 Dec; 20(12):1905-11. PubMed ID: 25072780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.